Abstract:Pancreatic cancer is a significant challenge in oncology due to its aggressive nature and complex management, leading to high mortality rates and a dismally low 5-year survival rate. Approximately 85% of cases manifest as adenocarcinoma, while endocrine tumors constitute less than 5%. Borderline resectable and locally advanced pancreatic cancers are particularly difficult to treat due to vascular involvement, which complicates complete resections and increases morbidity. Various therapeutic modalities aim to overcome these challenges and improve patient outcomes. Traditionally, upfront surgery was the standard for resectable tumors, with multimodal chemotherapy being central to treatment. Understanding surgical anatomy is pivotal in enhancing surgical outcomes and patient survival. Resectability challenges are several when seeking to achieve R0 resections, particularly for borderline resectable tumors. Various classification systems—the MD Anderson criteria, the NCCN criteria, the AHPA/SSAT/SSO consensus statement, and the Alliance definition—assess tumor involvement with major blood vessels, with the first of these systems being broadly accepted. Vascular staging integration is also important, with the Ishikawa staging system using preoperative imaging to assess venous involvement. Furthermore, neoadjuvant therapy enhances treatment effectiveness by addressing micro-metastatic disease early, increasing R0 resection chances, and downstaging tumors for optimal surgery. Insights from the Fox Chase Cancer Center's neoadjuvant treatment approach highlight the importance of a multidisciplinary strategy when advancing therapy and improving patient prognosis. This commentary, inspired by Dr. Sanjay S. Reddy's Keynote Conference during MedNews week, highlights current advancements and ongoing challenges in the treatment of pancreatic cancer, emphasizing the need for a comprehensive, multidisciplinary approach to improve outcomes.

Progress of Pancreatic Tumor Researches in the Pancreas 2018 of Johns Hopkins Hospital

Recent advances in basic research, clinical diagnosis and treatment of pancreatic cancer in 2016

Advances in pancreatic cancer research from 2017 annual meeting of the American Society of Clinical Oncology

Advances in Basic Research, Clinical Diagnosis and Treatment of Pancreatic Cancer in 2020

Advances in basic research, clinical diagnosis and treatment of pancreatic cancer in 2021

Advances in basic research,clinical diagnosis and treatment of pancreatic cancer in 2023

Insight of Pancreatic Cancer: Recommendations for Improving Its Therapeutic Efficacy in the Next Decade

Recent Advances in Basic Research, Clinical Diagnosis and Treatment of Pancreatic Cancer in 2015

[Ten Directions for Improving Clinical Therapeutic Effect of Pancreatic Cancer in the Future].

Immunotherapy in Pancreatic Cancer: New Hope or Mission Impossible?

Guidelines for the Diagnosis and Treatment of Pancreatic Cancer in China (2021)

Different therapies in pancreatic cancer treatment

Pancreatic cancer treatment: better, but a long way to go

Pancreatic cancer: diagnosis and treatments

The molecular biology of pancreatic adenocarcinoma: translational challenges and clinical perspectives

Thinking in the confusion, advancing in the challenges:hotspots in the comprehensive treatment of pancreatic carcinoma

Advancing Pancreatic Cancer Surgical Treatments and Proposal of New Approaches

Current Status and Future Prospect of Surgical Treatment for Pancreatic Cancer

Research Progress of Pancreas-Related Microorganisms and Pancreatic Cancer

Recent Advances in the Treatment of Pancreatic Cancer

Research progress in the establishment of pancreatic cancer models and preclinical applications